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Objectives: One of the most significant complications seen after the maze procedure
for atrial fibrillation is excessive fluid retention, with subsequent pulmonary complica-
tions. To address this problem we recently started treating all patients prophylactically
with a continuous infusion of furosemide starting immediately after the operation.
Methods: Seventy-five consecutive patients with statistically similar demographic
characteristics were divided into two groups. In the continuous infusion group (n =
36) furosemide was given intravenously as a continuous infusion at a dose of 2 to
15 mg/h for the first 48 hours after the operation, and in the bolus dose group (n =
39) furosemide was administered in bolus doses (50-100 mg) to maintain a targeted
daily urinary output of 25 to 50 mL/kg. Hemodynamic data, urinary output, fluid
balance, daily weights, and pulmonary complications were recorded during the first
48 hours after the operation.
Results: The mean postoperative urinary output was higher, the total furosemide
dose was lower, and the pulmonary complications were fewer in the continuous
infusion group than in the bolus dose group. Three patients in the bolus dose group
were reintubated after the operation, whereas none in the continuous infusion group
were reintubated. Supplemental oxygen requirements were greater in the bolus dose
group (7 vs 4 patients, P < .05). In the bolus dose group, 4 patients (10%) required
thoracentesis and 3 patients (8%) required chest tube insertions for postoperative
pleural effusions, in contrast with 1 patient (3%) each in the continuous infusion
group (P < .05).
Conclusion: Despite a smaller total dose relative to bolus infusion, prophylactic
continuous furosemide infusion decreased the adverse pulmonary complications
associated with excessive fluid retention in patients undergoing the maze procedure
for atrial fibrillation.
The maze procedure has become a safe and effective surgical treat-ment for medically refractory atrial fibrillation.1,2 Our experienceand that of others has revealed that after the maze procedure patientstend to retain large amounts of fluid, which may lead to symptomaticpleural effusion and pulmonary edema. The fluid retention phenom-enon occurs in as many as 30% of patients after the maze proce-
dure.2,3 The suggested mechanism is the decreased secretion of atrial natriuretic
peptide (ANP) by atrial tissue with subsequent abrupt reduction in circulating
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ANP.2,4 Other studies have supported this finding by
demonstrating a significant decrease in ANP levels in the
plasma after successful nonsurgical cardioversion.5,6 We
have also demonstrated that patients who have undergone
the maze procedure have significantly higher levels of sys-
temic arginine vasopressin and aldosterone than those of
patients who have undergone coronary artery bypass graft-
ing. Both mechanisms may contribute to fluid retention
after the maze procedure.
Several studies have demonstrated that continuous
furosemide infusion results in a greater diuresis than is seen
with bolus administration of the drug.6-12 In an effort to
minimize the risk of fluid retention and its associated com-
plication, we therefore recently tested a new protocol for
diuresis management of patients after the maze procedure.
In this regimen we treat patients with a continuous infusion
of furosemide starting at the time of admission to the inten-
sive care unit immediately after the operation and for 48
hours thereafter. This article reports the effects of continu-
ous furosemide infusion on fluid balance in patients after
the maze procedure, including the effect of such treatment
on the incidence of pulmonary complications.
Methods
Between June 1997 and January 1999 we performed 90 maze pro-
cedures. Fifty-two patients had the maze procedure as the only
operation and 38 patients had a total of 60 different procedures
combined with the maze procedure. Ten patients had coronary
artery bypass grafting, 37 had mitral valve operations (19 patients
underwent mitral valve repair), 3 patients had tricuspid valve
repair, 6 patients had aortic valve replacement, and 4 patients had
the maze procedure combined with repair of congenital anomalies.
In 30 cases the maze procedure was performed with a minimally
invasive approach; however, all patients in this study underwent
the maze III procedure, without the amputation of both right and
left atrial appendages.
Fifteen patients were excluded from the study for the following
reasons: 7 patients (3 in the continuous intravenous infusion group)
had preoperative creatinine levels higher than 1.5 mg/dL, and 8
patients (3 in the continuous intravenous infusion group) had hemo-
dynamic instability requiring significant inotropic support. The
TABLE 1. Patient data
Continuous infusion group Bolus dose group
Total (n = 75) (n = 36) (n = 39) P value
Age (y)
Mean 52 52 51
Range 24-77 33-72 24-77 >.05
Male
No. 55 28 27
% 73% 77% 69% >.05
Procedure type (No.)
Maze procedure only 49 24 25 >.05
Maze procedure and other procedure 26 12 14 >.05
Minimally invasive maze procedure 30 18 12 <.05
Cardiopulmonary bypass time (min) 163.6 ± 36.3 147.0 ± 22.0 179.0 ± 40.2 >.05
Crossclamp time (min) 107.4 ± 29.6 97.5 ± 20.7 116.5 ± 33.7 >.05
Baseline creatinine (mg/dL) 1.03 ± 0.11 1.02 ± 0.08 >.05
Postoperative cardiac index (L · min–1 · m–2) 2.53 ± 0.27 2.67 ± 0.29 >.05
TABLE 2. Pulmonary complications
Continuous infusion group (n = 36) Bolus dose group (n = 39)
No. % No. % P value
Pleural effusion
Small 2 5.5 6 15 <.05
Medium 1 3 4 10 <.05
Large 1 3 3 8 <.05
Pulmonary edema
Oxygen supplementation 4 10 0 0 >.05
Reintubation 7 18 3 39 <.05
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remaining 75 consecutive patients (Table 1) were randomly divided
into two groups according to the diuretic protocol, a group treated
with furosemide continuous intravenous therapy (n = 36) and a
group treated with bolus furosemide intravenous therapy (n = 39).
Diuresis Management
The target daily urinary output during the first 4 postoperative
days was between 25 and 50 mL/kg, with an emphasis on main-
taining negative fluid balance. The first-line diuretic used was
furosemide given intravenously for the first 48 to 72 hours as con-
tinuous infusion in the continuous infusion group (2-15 mg/h) and
as bolus therapy (50-100 mg bolus) in the bolus dose group. In
both groups if the targeted urinary output could not be achieved
with furosemide, dopamine at a dopaminergic dose (1-2 µg · kg–1
· min–1) was added. Spironolactone at 75 mg/d was orally admin-
istered immediately after extubation and maintained for 6 postop-
erative weeks in both patient groups.
Inotropic Support
Dobutamine (2-5 µg · kg–1 · min–1) was started for all patients dur-
ing weaning from cardiopulmonary bypass and continued until the
second postoperative day.13 There was no significant difference
between the groups with respect to the total dose of dobutamine used.
Extubation, Oxygen Supplementation, and
Reintubation Criteria
Patients were kept lightly sedated with an intravenous propofol infu-
sion until they fulfilled criteria for extubation.14 Supplemental oxy-
gen was given to patients by either nasal cannula or face mask.
Patients were supported with oxygen when oxygen saturation could
not be maintained above 92% on room air. Reintubation was insti-
tuted when acceptable oxygen saturation could not be maintained
despite the use of 100% oxygen with a nonrebreathing mask or
when the respiratory rate to tidal volume (liters) was 90 with sub-
jective shortness of breath, PaCO2 retention (>50 mm Hg), and a pH
of 7.3 or lower.15
Parameters Checked
This study was done to assess our new protocol-guided diuresis
after the maze procedure. We collected hemodynamic data from
all patients’ pulmonary artery catheter monitoring during the first
48 hours afer the operation. Urinary outputs, total fluid balances,
and the times required to return to preoperative weight were cal-
culated for all patients. Pulmonary complications related to fluid
retention were documented and listed in all cases.
Statistical Analysis
We constructed multivariate models with ordinary least squares lin-
ear regression. Intergroup differences were compared using analysis
of variance. A 2-tailed Spearman ρ coefficient was calculated to
assess the correlation between the dose of furosemide and urinary
output. All statistical analyses were performed with the Statistical
Package for the Social Sciences version 8.0 (SPSS Inc, Chicago, Ill).
Results
Patient demographic characteristics were evenly matched
between groups with respect to age, sex distribution, baseline
creatinine level, cardiopulmonary bypass and crossclamp
times, and postoperative cardiac index. A slightly higher per-
centage of patients in the continuous infusion group under-
went a minimally invasive maze procedure; otherwise, both
groups underwent similar surgical procedures (Table 1).
Fluid Balance and Urinary Output
The main concern after the maze procedure is fluid reten-
tion. The consequences of fluid overload are mainly pul-
monary complications. The vast majority of the patients
(95%) in the continuous infusion group had negative fluid
balance on postoperative days 0, 2, 3, and 4, whereas only
52% of patients in the bolus dose group did so on postoper-
ative days 0, 1, 2, and 3. There was no difference between
the groups with respect to fluid balance on postoperative
day 1. Only on postoperative day 4 did more than 90% of
patients in the bolus dose group have negative fluid balance.
This study correlates with previous studies that have
shown the advantage of continuous intravenous furosemide
therapy over bolus intravenous furosemide therapy with
respect to urinary output. Urinary output was higher in the
continuous infusion group patients on every postoperative
day and reached statistical significance on postoperative
days 0, 2, 3 and 4 (Figure 1). The total dose of furosemide,
however, was significantly lower in the continuous infusion
group, despite their higher urinary output (2.8 ± 2.2 mg/kg
for the continuous infusion group vs 4.7 ± 2.19 mg/kg for
the bolus dose group, P < .027). Mean daily urinary output
was highly influenced by the presence of a continuous
furosemide infusion (P < .001). A dose-dependent correla-
tion was observed between the continuous furosemide infu-
sion dose and urinary output (Spearman ρ = 0.43, P < .001).
Multivariate analysis showed that urinary output was
positively correlated with performance of a minimally inva-
Figure 1. Perioperative urinary output. Open diamonds, The con-
tinuous infusion group; filled squares, the bolus dose group.
Asterisk indicates P < .05.
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sive procedure (P = .01), female sex (P = .03), the presence
of a continuous furosemide drip (P < .0001), and the total
dose of furosemide (P = .03). Our model, after adjustment
for sex and minimally invasive procedures, demonstrated
that continuous intravenous furosemide therapy was associ-
ated with a significant higher urinary output. Urinary output
in this series did not correlate with the complexity of the
procedure performed, cardiopulmonary bypass time, cross-
clamp time, age, postoperative intensive care unit stay, intu-
bation time, and the use of diuretics other than furosemide
and spironolactone.
Pulmonary Complications
Observed pulmonary complications can be divided into two
categories, those primarily related to oxygenation or ventila-
tion abnormalities secondary to pulmonary congestion or
edema and those related to hypoxemia secondary to pleural
effusion. Patients in both categories were treated with addi-
tional diuretics. Table 2 charts the results for each group
according to the category of pulmonary complications. Small
pleural effusions were those with mild blunting of the
costophrenic angle without compromised systemic oxygena-
tion, medium were those with moderate costophrenic angle
blunting extending anteriorly and some degree of impairment
of oxygenation, and large pleural effusions were substantial
effusions obliterating the costophrenic angle with a significant
impairment of oxygenation. Relative to the continuous infu-
sion group the bolus dose group had a statistically significant
higher number of patients with pleural effusions in each sub-
category. Greater numbers of the bolus dose group patients
required supplemental oxygen therapy, and all reintubations
occurred in the bolus dose group. None of the reintubations
were for unstable hemodynamic parameters or premature
extubation. One patient in the bolus dose group had both pul-
monary edema and a large pleural effusion and was treated
with diuretics, tube thoracostomy, and reintubation.
Return to Baseline Weight
Return to preoperative weight occurred more rapidly in the
continuous infusion group (4 ± 1.6 days) than in the bolus
dose group (9.3 ± 3.5 days, P < .036). Multivariate analysis
showed that the presence of a continuous furosemide drip
was correlated with a decreased interval to return to preop-
erative weight (P < .001). Similarly, an increased dose of
furosemide administered was correlated with the patient’s
weight (P = .004).
Mechanical Ventilation
The time to initial extubation was greater in the bolus dose
group (13.3 ± 15.8 hours) than in the continuous infusion
group (6.2 ± 5.6 hours, P = .013). Multivariate analysis
demonstrated that time to extubation was correlated with
performance of a minimally invasive procedure (P = .031).
This correlation is important, because the maze procedure is
currently done with a minimally invasive approach in more
than 70% of our cases.
Discussion
Cardiopulmonary bypass for cardiac surgery results in sig-
nificant fluid accumulation. Longer bypass times lead to
greater fluid retention.16-20 The maze procedure is a rela-
tively long procedure, especially when combined with valve
or coronary artery bypass graft operations. Patients under-
going the maze procedure are thus predisposed toward
greater fluid accumulation by of the duration of the opera-
tion itself. Additionally, our experience and that of other
groups show enhanced fluid retention in patients after the
maze procedure relative to other types of cardiac opera-
tions.2,3 One of the suggested mechanisms is the abrupt
decreased postprocedure ANP levels along with cardiover-
sion to sinus rhythm.4,5 Recently we showed that both argi-
nine vasopressin and aldosterone circulating levels are high
after the maze procedure. Because of these higher levels,
patients have higher tendency to retain fluids. Fluid reten-
tion and related complications were documented in as many
as 30% of our patients after the maze procedure.2,3
Several studies have demonstrated the effectiveness of
postoperative furosemide infusion in mitigating fluid reten-
tion.6-12 Continuous infusions result in a more consistent
urinary output, lower urinary loss of electrolytes, and fewer
alterations in fluid balance, as reflected by altered cardiac
index and filling pressures.7,8,12
This study was designed to explore the benefits of proto-
col-guided diuretic management for patients undergoing the
maze procedure and to determine whether continuous and
intermittent dosing of furosemide would lead to clinically
relevant differences in outcomes. Our results demonstrated
several beneficial effects of continuous furosemide infusion
relative to intermittent dosing. Total urinary output
increased in the continuous infusion group despite a reduc-
tion by half of the total dose of furosemide. Continuous
infusion did not adversely affect hemodynamics even as it
sustained diuresis, and urinary output was easily titrated by
changing the infusion rate. Most important, the postopera-
tive course was improved, as reflected in more rapid return
to baseline weight, maintenance of negative fluid balance in
the immediate postoperative period, and fewer pulmonary
complications, especially the absence of reintubation (Table
2). Attainment of negative fluid balance, with its resultant
decrease in the time to return to baseline weight, was related
to continuous furosemide therapy and to the diminished use
of colloid necessary to maintain intravascular volume with
bolus furosemide therapy. Negative fluid balance is critical
to decreasing pulmonary complications.
We did not find a positive effect of continuous therapy
on urinary output or negative fluid balance on postoperative
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day 1 (Figure 1). Interestingly, most of the pulmonary con-
gestion and edema occurred on postoperative day 2. We sur-
mise that this is because 95% of patients in the continuous
infusion group, versus only 52% in the bolus dose group,
had a negative fluid balance on postoperative day 1. Earlier
negative fluid balance could have protected patients in the
bolus dose group from pulmonary complications despite the
lack of negative fluid balance that day. The effectiveness of
continuous furosemide therapy may be due to the attenua-
tion of the impact of low levels of ANP along with higher
levels of aldosterone and arginine vasopressin in patients
after the maze procedure.
Minimizing morbidity related to fluid retention did not
lead to a decrease in overall hospital stay. It is possible that
a return to stable sinus rhythm has a much greater influence
on hospital stay than does achievement of negative fluid
balance.
Our protocol for all patients after the maze procedure
was derived in part from this study. Patients receive contin-
uous infusions of both furosemide (2-15 mg/h) and dobuta-
mine (2-5 µg · kg–1 · min–1) for the first 48 postoperative
hours. At the time of extubation, and for 6 weeks afterward,
spironolactone (75 mg orally daily) is added to the diuretic
therapy. Spironolactone, initially added because it is a
diuretic with a different mechanism of action than
furosemide, may also improve overall cardiac perfor-
mance.21 This combined therapeutic regimen has led to sig-
nificant improvements in the postoperative course of
patients after the maze procedure, with or without other car-
diac surgical procedures.
In summary, we have demonstrated that continuous
furosemide therapy after the maze procedure is a more
effective method of achieving higher constant urinary out-
put than intermittent bolus therapy. Continuous furosemide
infusion results in significant reductions in fluid accumula-
tion and pulmonary complications.
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